Table 5.
Baseline–to–3‐Year Change in Quality of Life in Subgroups by AF Type and Final Good Arrhythmia Control
| AF Type | Good Arrhythmia Control | N | EQ‐5D | EQ‐VAS | ||||
|---|---|---|---|---|---|---|---|---|
| Change | P 1 | P 2 | Change | P 1 | P 2 | |||
| PAF | Off AADs | 174 | +9.1±14.3 | <0.00001 | 0.19 | +6.9±14.9 | <0.00001 | 0.0003 |
| On AADs | 42 | +0.3±10.4 | 0.85 | 0.14 | +3.0±12.0 | 0.11 | 0.63 | |
| Absent | 34 | −3.4±12.4 | 0.12 | 0.10 | −2.3±13.3 | 0.31 | 0.88 | |
| LSPAF | Off AADs | 84 | +11.6±13.8 | <0.00001 | +13.8±12.0 | <0.00001 | ||
| On AADs | 22 | +4.6±12.2 | 0.09 | +4.5±11.5 | 0.08 | |||
| Absent | 15 | +3.2±14.1 | 0.39 | −1.7±9.1 | 0.47 | |||
Data shown as mean±SD. 5D indicates 5‐dimensional descriptive system; AAD, antiarrhythmic drug; AF, atrial fibrillation; LSPAF, long‐standing persistent AF; PAF, paroxysmal AF; VAS, visual analog scale.
P1=P‐value of t test for dependent samples (baseline vs 3‐year follow‐up). P2=P‐value of t test for independent samples (PAF vs LSPAF).